UTHR - ユナイテッド・セラピュ―ティクス （United Therapeutics Corporation）UTHRのニュース
Top 5 4th Quarter Trades of TOBAM 2023/02/02 20:00:16 GuruFocus
Related Stocks: EA , UTHR , BDX , TTWO , LVS ,
Liquidia stock gains after PTAB denies United Therapeutics request for patent rehearing 2023/02/02 19:03:54 Seeking Alpha
Liquidia (LQDA) rose 6.3% after a U.S. patent court denied a request for a rehearing of the United Therapeutics (UTHR) patent invalidation decision. The Patent Trial and Appeal Board…
United Therapeutics Corp. PT Raised to $330 at UBS 2023/02/02 14:22:15 Investing.com
https://www.investing.com/news/pro/united-therapeutics-corp-pt-raised-to-330-at-ubs-432SI-2994289
This Insider Just Sold Shares of United Therapeutics Corp 2023/01/25 18:30:07 GuruFocus
Related Stocks: UTHR ,
United Therapeutics (UTHR) Presents At 41st Annual Healthcare Conference - Slideshow (NASDAQ:UTHR) 2023/01/20 12:49:10 Seeking Alpha
The following slide deck was published by United Therapeutics Corporation in conjunction with this event.
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis 2022/10/11 10:00:00 Wallstreet:Online
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled in the phase 3 TETON 2 study which will evaluate Tyvaso in 396 adult patients with idiopathic pulmonary fibrosis (IPF) at sites outside the United States and Canada. This second registration study is part of the broader global TETON program evaluating Tyvaso for the
Argus Positive on United Therapeutics Corp. , ''Discounted price offers buying opportunity'' 2022/09/22 11:04:02 Investing.com
https://www.investing.com/news/pro/argus-positive-on-united-therapeutics-corp--discounted-price-offers-buying-opportunity-432SI-2897043
United Therapeutics initiated at outperform at Wedbush on growth and innovation (UTHR) 2022/09/19 15:01:28 Seeking Alpha
Wedbush has initiated United Therapeutics (UTHR) with an outperform rating saying that the pharma, is poised for growth and has a strong pipeline.
Wedbush Assumes United Therapeutics Corp. at Outperform 2022/09/19 10:52:01 Investing.com
https://www.investing.com/news/pro/wedbush-assumes-united-therapeutics-corp-at-outperform-432SI-2894675
Was anything positive for United Therapeutics Corporation (UTHR) stock last session? 2022/09/01 12:48:00 US Post News
In Wednesday’s session, United Therapeutics Corporation (NASDAQ:UTHR) marked $226.62 per share, up from $218.97 in the previous session. While United Therapeutics Corporation has overperformed by 3.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UTHR rose by 5.46%, with highs and lows ranging from $245.48 to […]
Argus Positive on United Therapeutics Corp. , ''Discounted price offers buying opportunity'' 2022/09/22 11:04:02 Investing.com
https://www.investing.com/news/pro/argus-positive-on-united-therapeutics-corp--discounted-price-offers-buying-opportunity-432SI-2897043
United Therapeutics initiated at outperform at Wedbush on growth and innovation (UTHR) 2022/09/19 15:01:28 Seeking Alpha
Wedbush has initiated United Therapeutics (UTHR) with an outperform rating saying that the pharma, is poised for growth and has a strong pipeline.
Wedbush Assumes United Therapeutics Corp. at Outperform 2022/09/19 10:52:01 Investing.com
https://www.investing.com/news/pro/wedbush-assumes-united-therapeutics-corp-at-outperform-432SI-2894675
Was anything positive for United Therapeutics Corporation (UTHR) stock last session? 2022/09/01 12:48:00 US Post News
In Wednesday’s session, United Therapeutics Corporation (NASDAQ:UTHR) marked $226.62 per share, up from $218.97 in the previous session. While United Therapeutics Corporation has overperformed by 3.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UTHR rose by 5.46%, with highs and lows ranging from $245.48 to […]
United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation 2022/08/31 22:40:00 Business Wire
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics’ U.S. patents 9,593,066 (the ’066 patent) and 10,716,793 (the ’793 patent). This litigation concerns whether Liquidia Technologies, Inc.’s proposed treprostinil inhalation powder, YutrepiaTM, wou